Objective. Patients presenting with both arthralgia and antibodies to cyclic citrullinated peptide (anti-CCP) have an increased risk of developing rheumatoid arthritis (RA). To further characterize this patient group and shed more light on its relation with clinically manifest early arthritis and established RA, an immunogenetic and serological analysis was performed.
Introduction
Antibodies to cyclic citrullinated peptide (anti-CCP) often precede the development of rheumatoid arthritis (RA) and can therefore be used to detect those at risk for the development of RA. [1] [2] [3] Another major risk factor for RA is the shared epitope (SE) at the HLA-DRB1 locus. 4, 5 The SE hypothesis postulates that highly conserved amino acid sequences bordering the peptide binding groove of the HLA-DRB1 molecule are involved in the pathogenesis of RA, e.g. by enabling the presentation of arthritogenic peptides to T cells. 6 In support of the latter concept it has been shown that the DRB1*0401 peptide binding groove allows for a high affinity interaction with citrullinated peptides, resulting in efficient antigen presentation. 7 In a study analyzing preclinical blood samples of RA patients the highest risk for RA was associated with the presence of both anti-CCP and SE. 8 Recently, it was suggested that the increased risk for RA in SE positive undifferentiated arthritis is in fact not due to the SE, but to anti-CCP positivity. 9 In the latter study, the presence of SE alleles was associated with significantly higher levels of anti-CCP antibodies, suggesting that the SE alleles act as classic immune response genes. Therefore, the effect of the SE on RA development may be mediated through anti-CCP levels.
Patients presenting with both arthralgia and anti-CCP probably confer a high risk for the development of arthritis, although this patient group has not been extensively studied. We assessed the frequency of SE and levels of anti-CCP in these patients, and compared this with early and established RA.
Patients and methods

Study Population
The frequency of SE positivity in anti-CCP antibody positive unrelated Dutch Caucasians aged 
Laboratory investigations
Anti-CCP levels were determined using the serum samples that were obtained at inclusion by second-generation anti-CCP ELISA (Axis Shield, Dundee, United Kingdom). The cut-off level for anti-CCP antibody positivity was set at 5 Arbitrary Units/ml (AU) (according to the manufacturer's instructions). Sera reaching 1000 AU/ml were not further diluted.
HLA-DQ typing was performed as described previously. 13 The HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0410 and *1001 alleles were taken to contain the SE. HLA-DRB1 SE carrier status (one or two SE copies) was inferred from HLA DQA1-DQB1 haplotypes using the strong linkage disequilibrium (LD) with HLA-DRB1 alleles in Caucasians. 14 28 ( 
SE negative arthralgia patients have low anti-CCP levels when compared to arthritis patients
Discussion
In this first report on HLA typing in patients with anti-CCP positive arthralgia we observed that the anti-CCP positive arthralgia group includes a relatively large SE-negative subgroup of patients compared to anti-CCP positive early arthritis group and established RA group.
However, anti-CCP positive arthralgia patients are clearly more often SE positive than Caucasian population healthy controls (58% versus 26-46 %). [16] [17] [18] The present study also shows that the SE-negative arthralgia group has relatively low anti-CCP levels compared to an anti-CCP positive early arthritis group and an established RA group. In contrast, SE positive arthralgia seems to reflect pre-rheumatoid arthritis since anti-CCP levels in patients with SE positive arthralgia are comparable to those found in SE positive arthritis patients. Our study reconciles both results since we show that only in anti-CCP positive arthralgia the SE is associated with higher anti-CCP levels, suggesting that the SE only operates on anti-CCP levels in the early phase up to early arthritis, but not in the later transition from early arthritis to established RA. This supports the conclusion that the SE does not itself predispose to development of RA but rather operates through higher anti-CCP levels, not only in the clinical phase 19 but also in the preclinical stages of RA. The presence in the arthralgia group of a relatively large group of SE negative patients with low anti-CCP levels compared to the arthritis groups suggests that among SE-negative arthralgia patients development of arthritis is restricted to patients with high anti-CCP levels. Alternatively, this could mean that a large part of the SE positive RA patients do not go through a stage of anti-CCP-positive arthralgia but rather simultaneously develop frank arthritis with the onset of arthralgia. The differences in observed anti-CCP levels were probably not due to age effects. In line with previous literature 20 , we did not observe an effect of age on anti-CCP levels in the three patient groups, neither when analyzed individually nor when combined. Furthermore, age was similar among the SE negative and positive arthralgia patients (data not shown).
In summary, anti-CCP positive arthralgia patients have a relatively low frequency of the SE compared to anti-CCP positive early and established RA. Furthermore, these patients have relatively low anti-CCP levels. In later stages, the SE is not associated with differences in anti-CCP levels. This correlates with observations reported earlier that the presence of the SE, together with anti-CCP positivity increases the risk for RA, but that the SE does not influence the transition of anti-CCP positive early arthritis to rheumatoid arthritis. Together these findings suggest that the SE may influence RA risk through effects on anti-CCP levels.
Longitudinal follow-up of arthritis development in arthralgia patients may further clarify the effect of the SE and anti-CCP (levels) on RA development.
